Crossmark

Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

Crossref DOI link: https://doi.org/10.1016/j.nrleng.2021.06.006

Published Print: 2024-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Meca-Lallana, J.E.

Álvarez-Cermeño, J.C.

Casanova Estruch, B.

Izquierdo Ayuso, G.

Ortiz Castillo, R.

Rodríguez-Antigüedad, A.

Calles Hernández, C.
Funding

Funding for this research was provided by:

Sanofi
License Information

Text and Data Mining valid from 2024-06-01

Text and Data Mining valid from 2024-06-01

Version of Record valid from 2023-04-26
More Information

This article is maintained by: Elsevier

Article Title: Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study

Journal Title: Neurología (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.nrleng.2021.06.006

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.nrl.2021.06.007

Content Type: article

Copyright: © 2023 Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Neurología.